![]() |
市場調查報告書
商品編碼
1715188
2031年北美液體活體組織切片採血管市場預測—區域分析—按產品、材料、應用和最終用戶North America Blood Collection Tubes for Liquid Biopsy Market Forecast to 2031 - Regional Analysis - by Product, Material, Application, and End User |
2023年北美液體切片採血管市場價值為443.8594億美元,預計到2031年將達到1,684.6730億美元;預計2023年至2031年的複合年成長率為18.1%。
癌症盛行率上升推動北美液體活體組織切片採血管市場發展
世界各地的衛生系統都見證著癌症發生率的急劇上升。世界衛生組織(WHO)將癌症列為全球第二大死因。根據世界癌症研究基金會國際發表的資料,2022年全球新增癌症病例約2,000萬例。此外,根據世界衛生組織(WHO)發布的資料,2020年全球有近1,000萬人死於癌症。美國國家衛生統計中心的資料估計,到2024年,美國新診斷的癌症病例可能達到200萬人。此外,預計到2024年,美國將有約61萬人死於癌症。
早期預後、腫瘤異質性檢測、降低成本和患者舒適度是液體活體組織切片相對於其他癌症診斷方法的一些優勢。因此,在預測期內,隨著癌症盛行率的上升,人們對液體活體組織切片的青睞度也在增加,因為它可以快速治療並提高癌症患者的生存率。液體切片檢查中使用的採血管在各組織的早期精準癌症檢測策略中發揮重要作用。因此,癌症盛行率的上升對北美液體活體組織切片採血管市場的成長做出了重大貢獻。
北美液體切片採血管市場概況
北美液體切片採血管市場分為美國、加拿大和墨西哥。隨著美國癌症發病率的飆升、創新診斷解決方案開發投入的增加以及重要市場參與者的存在,美國液體活體組織切片程序市場正在快速成長。美國國家癌症研究所估計,2024 年美國將新增約 200 萬例癌症病例,預計約有 611,720 人死於癌症。根據同一來源,每年每 10 萬人中約有 440.5 人被診斷出罹患癌症。組織切片檢查是用於肺癌診斷的高度侵入性技術。由於樣本不足可能導致此類活體組織切片結果不可靠,研究人員專注於開發用於肺癌診斷的液體活體組織切片技術。
北美液體切片採血管市場收入及預測(2031年)(百萬美元)
北美液體切片採血管市場細分
北美液體切片採血管市場分為產品、材料、應用、最終用戶、國家。
根據產品,北美液體切片採血管市場分為 ccfDNA/cfDNA 管、cfRNA 管、CTC 管、gDNA 管、細胞內 RNA 管等。 2023 年,ccfDNA/cfDNA 管部門佔據北美液體活體組織切片採血管市場的最大佔有率。
就材質而言,北美液體活體組織切片採血管市場分為塑膠和玻璃。 2023 年,塑膠部分在北美液體活體組織切片採血管市場中佔據較大佔有率。
根據應用,北美液體切片採血管市場分為體外診斷(IVD)和研究。 2023 年,體外診斷 (IVD) 領域在北美液體活體組織切片採血管市場中佔據較大佔有率。
就最終用戶而言,北美液體活體組織切片採血管市場分為基因診斷實驗室、研發中心、傳統診斷中心和其他。 2023 年,基因診斷實驗室部門佔據北美液體活體組織切片採血管市場的最大佔有率。
根據國家/地區,北美液體活體組織切片採血管市場分為美國、加拿大和墨西哥。 2023 年,美國佔據北美液體切片採血管市場的最大佔有率。
使徒科學; Biocept公司;精確科學公司; F.霍夫曼-羅氏有限公司; Greiner Bio-One International GmbH; MagBio Genomics 公司; Norgen Biotek 公司; QIAGEN NV;斯特雷克公司;和 Zymo Research Corporation 是北美液體活體組織切片採血管市場領先的公司之一。
The North America blood collection tubes for liquid biopsy market was valued at US$ 44,385.94 million in 2023 and is expected to reach US$ 1,68,467.30 million by 2031; it is estimated to register a CAGR of 18.1% from 2023 to 2031.
Increase in Prevalence of Cancer Fuels North America Blood Collection Tubes for Liquid Biopsy Market
Health systems across the world are witnessing an exponential increase in the prevalence of cancer. The World Health Organization (WHO) ranks cancer as the second-leading cause of mortality worldwide. According to data published by the World Cancer Research Fund International, ~20 million new cases of cancer were registered in 2022 globally. Moreover, as per the data published by the World Health Organization (WHO), nearly 10 million deaths were caused by cancer in 2020 across the world. The National Center for Health Statistics data estimates that the diagnosis of new cancer cases in the US is likely to reach 2 million in 2024. In addition, approximately 0.61 million people were anticipated to die in 2024 in the US due to cancer.
Early prognosis, tumor heterogeneity detection, reduced cost, and patient comfort are a few of the advantages of liquid biopsy over other cancer diagnostics approaches. Thus, the preference for liquid biopsy, allowing for quick treatment and enhancing cancer patients' survival rates, is increasing with the rise in cancer prevalence during the projection period. Blood collection tubes that are used in liquid biopsy play an instrumental role in the early and precise cancer detection strategies of various organizations. Thus, the increasing prevalence of cancer is contributing significantly to the growth of the North America blood collection tubes for liquid biopsy market .
North America Blood Collection Tubes for Liquid Biopsy Market Overview
The North America blood collection tubes for liquid biopsy market is segmented into the US, Canada, and Mexico. The market for liquid biopsy procedures is growing rapidly in the US with the surging prevalence of cancer, high spending on the development of innovative diagnostics solutions, and the presence of significant market players in the country. The National Cancer Institute estimates that ~2 million new cases of cancer would be registered in the US in 2024, and ~611,720 people are expected to die due to cancer. As per the same source, ~440.5 per 100,000 people are nearly diagnosed with cancer every year. Tissue biopsies are highly invasive techniques employed for lung cancer diagnosis. As the insufficiency of samples may result in nonreliable results in this type of biopsy, researchers focus on the development of liquid biopsy techniques for lung cancer diagnoses.
North America Blood Collection Tubes for Liquid Biopsy Market Revenue and Forecast to 2031 (US$ Million)
North America Blood Collection Tubes for Liquid Biopsy Market Segmentation
The North America blood collection tubes for liquid biopsy market is categorized into product, material, application, end user, country.
By product, the North America blood collection tubes for liquid biopsy market is segmented into ccfDNA/cfDNA Tubes, cfRNA Tubes, CTC Tubes, gDNA Tubes, intracellular RNA Tubes, and others. The ccfDNA/cfDNA Tubes segment held the largest share of the North America blood collection tubes for liquid biopsy market share in 2023.
In terms of material, the North America blood collection tubes for liquid biopsy market is segmented into plastic and glass. The plastic segment held a larger share of the North America blood collection tubes for liquid biopsy market share in 2023.
By application, the North America blood collection tubes for liquid biopsy market is bifurcated into in-vitro diagnostics (IVD) and research. The in-vitro diagnostics (IVD) segment held a larger share of the North America blood collection tubes for liquid biopsy market share in 2023.
In terms of end user, the North America blood collection tubes for liquid biopsy market is segmented into genetic diagnostic labs, research and development centers, conventional diagnostic centers, and others. The genetic diagnostic labs segment held the largest share of the North America blood collection tubes for liquid biopsy market share in 2023.
Based on country, the North America blood collection tubes for liquid biopsy market is segmented into the US, Canada, and Mexico. The US segment held the largest share of North America blood collection tubes for liquid biopsy market in 2023.
Apostle Sciences; Biocept Inc; Exact Sciences Corp; F. Hoffmann-La Roche Ltd; Greiner Bio-One International GmbH; MagBio Genomics, Inc; Norgen Biotek Corp; QIAGEN NV; Streck Inc; and Zymo Research Corporation are some of the leading companies operating in the North America blood collection tubes for liquid biopsy market.